278 related articles for article (PubMed ID: 21403841)
1. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.
Chia KM; Liu J; Francis GD; Naderi A
Neoplasia; 2011 Feb; 13(2):154-66. PubMed ID: 21403841
[TBL] [Abstract][Full Text] [Related]
2. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M
Breast Cancer Res; 2012 Jul; 14(4):R111. PubMed ID: 22817771
[TBL] [Abstract][Full Text] [Related]
3. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Naderi A; Chia KM; Liu J
Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548
[TBL] [Abstract][Full Text] [Related]
4. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer.
Naderi A; Hughes-Davies L
Neoplasia; 2008 Jun; 10(6):542-8. PubMed ID: 18516291
[TBL] [Abstract][Full Text] [Related]
5. Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M; Dowhan DH
Neoplasia; 2012 Apr; 14(4):283-96. PubMed ID: 22577344
[TBL] [Abstract][Full Text] [Related]
6. Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2.
Jiang K; Yang Z; Cheng L; Wang S; Ning K; Zhou L; Lin J; Zhong H; Wang L; Li Y; Huang J; Zhang H; Ye Q
J Biol Chem; 2013 Aug; 288(34):24590-9. PubMed ID: 23861392
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
Naderi A; Liu J
Cancer Lett; 2010 Dec; 298(1):74-87. PubMed ID: 20605569
[TBL] [Abstract][Full Text] [Related]
8. Targeting androgen receptor in estrogen receptor-negative breast cancer.
Ni M; Chen Y; Lim E; Wimberly H; Bailey ST; Imai Y; Rimm DL; Liu XS; Brown M
Cancer Cell; 2011 Jul; 20(1):119-31. PubMed ID: 21741601
[TBL] [Abstract][Full Text] [Related]
9. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
10. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.
Arias-Romero LE; Villamar-Cruz O; Pacheco A; Kosoff R; Huang M; Muthuswamy SK; Chernoff J
Oncogene; 2010 Oct; 29(43):5839-49. PubMed ID: 20711231
[TBL] [Abstract][Full Text] [Related]
11. The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells.
Shi M; Liu D; Duan H; Qian L; Wang L; Niu L; Zhang H; Yong Z; Gong Z; Song L; Yu M; Hu M; Xia Q; Shen B; Guo N
Breast Cancer Res Treat; 2011 Jan; 125(2):351-62. PubMed ID: 20237834
[TBL] [Abstract][Full Text] [Related]
12. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
Sengupta S; Schiff R; Katzenellenbogen BS
Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
[TBL] [Abstract][Full Text] [Related]
13. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.
Ariazi EA; Kraus RJ; Farrell ML; Jordan VC; Mertz JE
Mol Cancer Res; 2007 Jan; 5(1):71-85. PubMed ID: 17259347
[TBL] [Abstract][Full Text] [Related]
14. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
15. Identification of molecular apocrine breast tumours by microarray analysis.
Farmer P; Bonnefoi H; Becette V; Tubiana-Hulin M; Fumoleau P; Larsimont D; Macgrogan G; Bergh J; Cameron D; Goldstein D; Duss S; Nicoulaz AL; Brisken C; Fiche M; Delorenzi M; Iggo R
Oncogene; 2005 Jul; 24(29):4660-71. PubMed ID: 15897907
[TBL] [Abstract][Full Text] [Related]
16. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
17. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
18. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
[TBL] [Abstract][Full Text] [Related]
19. Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain.
Kawasaki Y; Sakimura A; Park CM; Tomaru R; Tanaka T; Ozawa T; Zhou Y; Narita K; Kishi H; Muraguchi A; Sakurai H
Sci Rep; 2016 Aug; 6():31502. PubMed ID: 27531070
[TBL] [Abstract][Full Text] [Related]
20. Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study.
Jinna ND; Van Alsten S; Rida P; Seewaldt VL; Troester MA
Breast Cancer Res Treat; 2023 Sep; 201(2):171-181. PubMed ID: 37438515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
